MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Malignant hyperthermia

Drug safety update

 December 2014: Intravenous dantrolene: risk of undissolved crystals

Important safety information

Dantrolene should only be administered by, or under the direct supervision of, personnel experienced in the use of dantrolene when used for malignant hyperthermia

Dantrolene is used in the treatment of malignant hyperthermia. It acts on skeletal muscle cells by interfering with calcium efflux, thereby stopping the contractile process and reducing muscle rigidity.

Pack Price
12 vial £612.00
36 vial (3 x 12 vials) £1,836.00